123 completed, 18 terminated, 9 unknown, 6 not yet recruiting. 62 Phase 2, 59 Phase 1, 25 Phase 3, 11 Phase 4, 1 Not applicable.
Follow nintedanib: new trials by email Literature Review of nintedanib trials Research Report on nintedanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis Antifibrotic therapy - Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis | Not yet recruiting | Bristol-Myers Squibb | 40 | 2026-08-01 | 2026-07-23 | |
| Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF) Nintedanib,Dextromethorphan, Nintedanib,Placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 60 | 2026-05-12 | 2026-05-13 |
| A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer Tislelizumab and nintedanib - Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 4 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 20 | 2026-05-01 | 2026-03-20 |
| A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants taladegib, nintedanib, pirfenidone - Idiopathic Pulmonary Fibrosis | Phase 1 | Recruiting | Endeavor Biomedicines, Inc. | 57 | 2026-04-28 | 2026-05-15 |
| Nintedanib for Improving Reproductive Outcomes in Adenomyosis Nintedanib, Progesterone - Adenomyosis of Uterus | Phase 3 | Not yet recruiting | Sun Yat-sen University | 328 | 2025-09-01 | 2025-09-09 |
| Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease Tocilizumab, Nintedanib, Standard therapy - Systemic Sclerosis, Interstitial Lung Disease | Phase 3 | Recruiting | National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland | 86 | 2025-07-01 | 2026-04-08 |
| A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants NAL ER, Pirfenidone, Nintedanib - Healthy Participants | Phase 1 | Completed | Trevi Therapeutics | 132 | 2025-06-30 | 2025-10-10 |
| A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis Ofev® - Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease | Active not recruiting | Boehringer Ingelheim | 2000 | 2025-06-17 | 2025-12-08 | |
| Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib Nintedanib 150 MG [Ofev] - Drug Interactions | Phase 1 | Completed | PureTech | 24 | 2024-12-17 | 2026-08-13 |
| Nintedanib Treatment in Unicentric Castleman Disease Nintedanib - Castleman Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 13 | 2024-11-01 | 2024-10-15 |
| Real-life-persistence to Antifibrotic Treatments Nintedanib, Pirfenidone - Idiopathic Pulmonary Fibrosis | Completed | Boehringer Ingelheim | 10646 | 2024-10-16 | 2026-04-15 | |
| A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib Part A: Placebo, Nintedanib, GSK3915393 - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | GlaxoSmithKline | 50 | 2024-10-07 | 2025-02-18 |
| A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants Nintedanib, BMS 986278 - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 71 | 2024-09-19 | 2025-03-14 |
| Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLC Nintedanib - NSCLC, Nintedanib | Unknown | Second Hospital of Shanxi Medical University | 40 | 2024-08-24 | 2024-08-26 | |
| A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib Nintedanib - Idiopathic Pulmonary Fibrosis, Diarrhoea | Completed | Boehringer Ingelheim | 18 | 2024-07-16 | 2026-05-13 | |
| RCT of Nintedanib in Fibrotic Sarcoidosis Nintedanib, Standard of care - Sarcoidosis, Pulmonary | Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 120 | 2024-06-30 | 2024-10-23 |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients Nintedanib, gefitinib, erlotinib, afatinib, osimertinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 1 / Phase 2 | Recruiting | China Medical University Hospital | 20 | 2024-02-23 | 2025-01-23 |
| Safety of Nintedanib in Real World in China nintedanib, pirfenidone - Pulmonary Fibrosis | Withdrawn | Boehringer Ingelheim | 2023-12-29 | 2024-12-10 | ||
| Prospective Clinical Study of Nintedanib to Inhibit Endometrial Fibrosis to Prevent Recurrence of Uterine Adhesions Nintedanib 100 MG [Ofev], Nintedanib 150 MG [Ofev] - Uterine Adhesions | Phase 2 / Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 90 | 2023-12-01 | 2022-12-02 |
Showing 20 of 175. Sign in to see all of them.
Idiopathic Pulmonary Fibrosis (36) · Lung Diseases, Interstitial (20) · Carcinoma, Non-Small-Cell Lung (18) · Pulmonary Fibrosis (11) · Ovarian Neoplasms (8) · Neoplasms (7) · Colorectal Neoplasms (5) · Recurrence (4) · Scleroderma, Systemic (4) · Breast Neoplasms (3) · Carcinoma, Hepatocellular (3) · Glioblastoma (3) · Prostatic Neoplasms (3) · Radiation Pneumonitis (3) · Small Cell Lung Carcinoma (3)
Boehringer Ingelheim (86) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Roswell Park Cancer Institute (4) · Assistance Publique - Hôpitaux de Paris (3) · Aktion Bronchialkarzinom e.V. (2) · Bristol-Myers Squibb (2) · Endeavor Biomedicines, Inc. (2) · Hospices Civils de Lyon (2) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Sunshine Lake Pharma Co., Ltd. (2) · AA Secord (1) · AHS Cancer Control Alberta (1) · ARCAGY/ GINECO GROUP (1)
United States (59) · Germany (44) · France (39) · United Kingdom (29) · Spain (26) · Belgium (24) · Italy (24) · Canada (21) · Japan (21) · Poland (18) · Australia (17) · Netherlands (16) · South Korea (15) · China (14) · Czechia (13)
Lisa Lancaster, M.D. (2) · Prof. Dr. Martin Wolf, MD (2) · Prof. Dr. Rudolf M. Huber, MD (2) · Alain Vergnenegre, MD (1) · Andrea Marseille, +4961327714188 (1) · Angeles A Secord, MD (1) · Anish Ambaram, M.D. (1) · Benedict Brockway, M.D. (1) · Bhanu Singh, M.D. (1) · Catherina Chang, M.D. (1) · Chia-Chi Lin, Ph.D (1)
PMID 37185961, PMID 33902584, PMID 31914963, PMID 32217654, PMID 24834811, PMID 24836310, PMID 26400368, PMID 27672117, PMID 28039616, PMID 28388260, PMID 28526798, PMID 29500603, PMID 30176872, PMID 30729456, PMID 30971229, PMID 33239000, PMID 37294870, PMID 12172553, PMID 23625328, PMID 24411639, PMID 24556663, PMID 24591665, PMID 25312396, PMID 25338318, PMID 25504994, PMID 25795637, PMID 26512876, PMID 26590673, PMID 26603056, PMID 27133759, PMID 27627050, PMID 28184431, PMID 28652319, PMID 28664834, PMID 28702806, PMID 28889759, PMID 28993537, PMID 29018526, PMID 29946005, PMID 30010751, PMID 30073583, PMID 30167310, PMID 30220235, PMID 30224318, PMID 30603797, PMID 31103412, PMID 31112379, PMID 31126332, PMID 31326319, PMID 31365829
2015 (12), 2008 (4), 2009 (4), 2018 (4), 2016 (3), P30CA016056 (3), 2019 (2), 2014 (1), 2023 (1), 2025 (1), P30CA022453 (1), P30CA060553 (1), U10CA027469 (1), U10CA180868 (1)